A portion of amino acids 376-502 from the human protein was used as the immunogen for the Melanoma gp100 antibody.
PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt]
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Application Notes:
The stated application concentrations are suggested starting points. Titration of the Melanoma gp100 antibody may be required due to differences in protocols and secondary/substrate sensitivity.
* VAT and and shipping costs not included. Errors and price changes excepted
